Table 2 The association of antiplatelet drugs with VAF for AVF
From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development | Number of Bleeding events (Control) |
|---|---|---|---|---|---|---|
Gröntoft et al [71] | Placebo-controlled | 258 (124) | Ticlopidine 250 mg 2× /day Pre | AVF thrombosis (28 days) | Equivalent risk (12% vs. 19%, P = 0.101) | None |
Dember et al [70] | Placebo-controlled | 877 (436) | Clopidgrel 75 mg/day (loading 300 mg) Pre | AVF suitable for HD (150–180 days) | Equivalent risk (61.8% vs. 59.5%, RR 1.05, 95% CI 0.94–1.17, P = 0.40) | 12 (13) NS |
Ghorbani et al [69] | Placebo-controlled | 93 (47) | Clopidogrel 75 mg/day Pre | Primary AVF failure (2 months) | Lower risk (21.6% vs. 5.2%, RR 0.72, 95% CI 0.41–1.01, P = 0.03) | None |
Irish et al [68] | Placebo-controlled | 406 (203) | Aspirin 100mg /day Pre | Primary AVF failure (12 months) | Equivalent risk (45% vs. 43%, RR 1.05, 95% CI 0.84–1.31, P = 0.68) | 10 (16) NS |